A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

Summary

This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month interval.

Timeline

Start

2020-06-17

Primary completion

2024-01-05

Completion

2024-01-05

Publications

• Jones JC, Tipton MD, Zolotas L, Maguire JD, Belanger K, Liu Y, Maansson R, O'Neill RE, Balmer P, Peyrani P, Beeslaar J. Immunogenicity and Safety of Extended Dosing Intervals for Pfizer Pentavalent MenABCWY Meningococcal Vaccination in Healthy Adolescents: Results from a Randomized, Phase 2b Study. Vaccines (Basel). 2026 Apr 15;14(4):352. doi: 10.3390/vaccines14040352.

Drugs

Indications